skip to main content
Idioma:
Refinado por: Nome da Publicação: Blood remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Brown, Jennifer R. ; Byrd, John C. ; Coutre, Steven E. ; Benson, Don M. ; Flinn, Ian W. ; Wagner-Johnston, Nina D. ; Spurgeon, Stephen E. ; Kahl, Brad S. ; Bello, Celeste ; Webb, Heather K. ; Johnson, Dave M. ; Peterman, Sissy ; Li, Daniel ; Jahn, Thomas M. ; Lannutti, Brian J. ; Ulrich, Roger G. ; Yu, Albert S. ; Miller, Langdon L. ; Furman, Richard R.

Blood, 2014-05, Vol.123 (22), p.3390-3397 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
2
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

O'Brien, Susan M. ; Lamanna, Nicole ; Kipps, Thomas J. ; Flinn, Ian ; Zelenetz, Andrew D. ; Burger, Jan A. ; Keating, Michael ; Mitra, Siddhartha ; Holes, Leanne ; Yu, Albert S. ; Johnson, David M. ; Miller, Langdon L. ; Kim, Yeonhee ; Dansey, Roger D. ; Dubowy, Ronald L. ; Coutre, Steven E.

Blood, 2015-12, Vol.126 (25), p.2686-2694 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
3
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Flinn, Ian W. ; Kahl, Brad S. ; Leonard, John P. ; Furman, Richard R. ; Brown, Jennifer R. ; Byrd, John C. ; Wagner-Johnston, Nina D. ; Coutre, Steve E. ; Benson, Don M. ; Peterman, Sissy ; Cho, Yoonjin ; Webb, Heather K. ; Johnson, David M. ; Yu, Albert S. ; Ulrich, Roger G. ; Godfrey, Wayne R. ; Miller, Langdon L. ; Spurgeon, Stephen E.

Blood, 2014-05, Vol.123 (22), p.3406-3413 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
4
Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling
Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling
Material Type:
Artigo 		Adicionar ao Meu Espaço

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling

Taylor, Samuel J. ; Dagger, Samantha A. ; Thien, Christine B.F. ; Wikstrom, Matthew E. ; Langdon, Wallace Y.

Blood, 2012-11, Vol.120 (19), p.4049-4057 [Periódico revisado por pares]

Washington, DC: Elsevier Inc

Texto completo disponível

Citações Citado por
5
VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Wang, Michael ; Barrientos, Jacqueline C. ; Furman, Richard R. ; Mei, Matthew ; Barr, Paul M. ; Choi, Michael Y. ; de Vos, Sven ; Kallam, Avyakta ; Patel, Krish ; Rule, Simon ; Flanders, Kate ; Jessen, Katti A. ; Riebling, Peter C. ; Graham, Patricia ; King, Lydia ; Schmidt, Elizabeth M. ; Lannutti, Brian J. ; Johnson, David M. ; Miller, Langdon L. ; Spurgeon, Stephen E.

Blood, 2020-11, Vol.136 (Supplement 1), p.13-14 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
FLT3 Inhibitor AC220 Is a Potent Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice
FLT3 Inhibitor AC220 Is a Potent Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice
Material Type:
Artigo 		Adicionar ao Meu Espaço

FLT3 Inhibitor AC220 Is a Potent Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice

Langdon, Wallace Y ; Dagger, Samantha A ; Taylor, Samuel J ; Thien, Christine B F ; Wikstrom, Matthew E

Blood, 2011-11, Vol.118 (21), p.642-642 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
7
Interleukin-6 Is a Significant Modifier of the Anemia Associated with Aging in Mice
Interleukin-6 Is a Significant Modifier of the Anemia Associated with Aging in Mice
Material Type:
Artigo 		Adicionar ao Meu Espaço

Interleukin-6 Is a Significant Modifier of the Anemia Associated with Aging in Mice

McCranor, Bryan J. ; Langdon, Jacqueline M. ; Prince, Olivier D. ; Yu, Qilu ; Berger, Alan E. ; Cheadle, Chris ; Civin, Curt I. ; Walston, Jeremy D. ; Xue, Qian-Li ; Roy, Cindy N.

Blood, 2012-11, Vol.120 (21), p.2094-2094 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
8
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Coutre, Steven E. ; Leonard, John P. ; Furman, Richard R. ; Barrientos, Jacqueline C. ; de Vos, Sven ; Flinn, Ian W. ; Schreeder, Marshall T. ; Wagner-Johnston, Nina D. ; Sharman, Jeff ; Boyd, Thomas E. ; Fowler, Nathan H ; Holes, Leanne M. ; Lannutti, Brian J. ; Johnson, Dave M. ; Miller, Langdon L ; Jahn, Thomas M.

Blood, 2012-11, Vol.120 (21), p.191-191 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
9
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Furman, Richard R. ; Sharman, Jeff P. ; Coutre, Steven E. ; Cheson, Bruce D. ; Pagel, John M. ; Hillmen, Peter ; Barrientos, Jacqueline C. ; Zelenetz, Andrew D. ; Kipps, Thomas J. ; Flinn, Ian ; Ghia, Paolo ; Eradat, Herbert ; Ervin, Thomas ; Lamanna, Nicole ; Hallek, Michael ; Coiffier, Bertrand ; Pettitt, Andrew R. ; Ma, Shuo ; Stilgenbauer, Stephan ; Cramer, Paula ; Aiello, Maria ; Johnson, Dave M. ; Miller, Langdon L. ; Li, Daniel ; Jahn, Thomas M. ; Dansey, Roger D. ; O'Brien, Susan M.

Blood, 2013-11, Vol.122 (21), p.LBA-6-LBA-6 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
10
Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study
Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Fowler, Nathan H ; de Vos, Sven ; Schreeder, Marshall T. ; Leonard, John P. ; Flinn, Ian W. ; Coutre, Steve ; Wagner-Johnston, Nina D. ; Sharman, Jeff ; Boccia, Ralph V. ; Barrientos, Jacqueline C. ; Boyd, Thomas E. ; Holes, Leanne M. ; Lannutti, Brian J. ; Johnson, David ; Jahn, Thomas M. ; Miller, Langdon L ; Godfrey, Wayne R

Blood, 2012-11, Vol.120 (21), p.3645-3645 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.